Genfit S.A. (GNFT) - Net Assets
Based on the latest financial reports, Genfit S.A. (GNFT) has net assets worth €52.47 Million EUR (≈ $61.35 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€216.68 Million ≈ $253.33 Million USD) and total liabilities (€164.21 Million ≈ $191.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Genfit S.A.'s assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €52.47 Million |
| % of Total Assets | 24.22% |
| Annual Growth Rate | 10.18% |
| 5-Year Change | N/A |
| 10-Year Change | 24.92% |
| Growth Volatility | 123.59 |
Genfit S.A. - Net Assets Trend (2003–2024)
This chart illustrates how Genfit S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore Genfit S.A. (GNFT) total assets for the complete picture of this company's asset base.
Annual Net Assets for Genfit S.A. (2003–2024)
The table below shows the annual net assets of Genfit S.A. from 2003 to 2024. For live valuation and market cap data, see Genfit S.A. (GNFT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €69.22 Million ≈ $80.93 Million |
+1.87% |
| 2023-12-31 | €67.95 Million ≈ $79.44 Million |
-28.12% |
| 2022-12-31 | €94.53 Million ≈ $110.51 Million |
-20.63% |
| 2021-12-31 | €119.10 Million ≈ $139.24 Million |
+836.90% |
| 2020-12-31 | €-16.16 Million ≈ $-18.90 Million |
-119.23% |
| 2019-12-31 | €84.06 Million ≈ $98.28 Million |
+301.48% |
| 2018-12-31 | €20.94 Million ≈ $24.48 Million |
-79.91% |
| 2017-12-31 | €104.23 Million ≈ $121.85 Million |
-27.01% |
| 2016-12-31 | €142.80 Million ≈ $166.94 Million |
+157.68% |
| 2015-12-31 | €55.42 Million ≈ $64.79 Million |
-21.32% |
| 2014-12-31 | €70.43 Million ≈ $82.34 Million |
+399.74% |
| 2013-12-31 | €14.09 Million ≈ $16.48 Million |
+106.22% |
| 2012-12-31 | €6.83 Million ≈ $7.99 Million |
+53.33% |
| 2011-12-31 | €4.46 Million ≈ $5.21 Million |
-46.87% |
| 2010-12-31 | €8.39 Million ≈ $9.81 Million |
-45.95% |
| 2009-12-31 | €15.52 Million ≈ $18.14 Million |
-30.66% |
| 2008-12-31 | €22.38 Million ≈ $26.17 Million |
-11.77% |
| 2007-12-31 | €25.37 Million ≈ $29.66 Million |
-8.65% |
| 2006-12-31 | €27.77 Million ≈ $32.47 Million |
+107.45% |
| 2005-12-31 | €13.39 Million ≈ $15.65 Million |
-4.37% |
| 2004-12-31 | €14.00 Million ≈ $16.37 Million |
+54.76% |
| 2003-12-31 | €9.04 Million ≈ $10.57 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genfit S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15238.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €12.50 Million | 18.06% |
| Other Comprehensive Income | €347.00K | 0.50% |
| Other Components | €446.95 Million | 645.65% |
| Total Equity | €69.22 Million | 100.00% |
Genfit S.A. Competitors by Market Cap
The table below lists competitors of Genfit S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plastika Kritis S.A.
AT:PLAKR
|
$399.74 Million |
|
MCI Management SA
WAR:MCI
|
$399.93 Million |
|
North American Construction Group Ltd
TO:NOA
|
$400.31 Million |
|
North American Financial 15
TO:FFN
|
$400.33 Million |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
$399.53 Million |
|
Wonderful Hi-Tech Co Ltd
TWO:6190
|
$399.31 Million |
|
Shinsung Tngsn
KO:005390
|
$399.30 Million |
|
Tera Light Ltd
TA:TRLT
|
$399.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genfit S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 67,951,000 to 69,224,000, a change of 1,273,000 (1.9%).
- Net income of 1,507,000 contributed positively to equity growth.
- Share repurchases of 61,000 reduced equity.
- New share issuances of 61,000 increased equity.
- Other comprehensive income decreased equity by 649,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.51 Million | +2.18% |
| Share Repurchases | €61.00K | -0.09% |
| Share Issuances | €61.00K | +0.09% |
| Other Comprehensive Income | €-649.00K | -0.94% |
| Other Changes | €415.00K | +0.6% |
| Total Change | €- | 1.87% |
Book Value vs Market Value Analysis
This analysis compares Genfit S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.00x to 5.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €1.15 | €8.08 | x |
| 2005-12-31 | €1.15 | €8.08 | x |
| 2006-12-31 | €2.39 | €8.08 | x |
| 2007-12-31 | €2.18 | €8.08 | x |
| 2008-12-31 | €1.93 | €8.08 | x |
| 2009-12-31 | €1.34 | €8.08 | x |
| 2010-12-31 | €0.70 | €8.08 | x |
| 2011-12-31 | €0.35 | €8.08 | x |
| 2012-12-31 | €0.45 | €8.08 | x |
| 2013-12-31 | €0.70 | €8.08 | x |
| 2014-12-31 | €3.07 | €8.08 | x |
| 2015-12-31 | €2.24 | €8.08 | x |
| 2016-12-31 | €5.32 | €8.08 | x |
| 2017-12-31 | €3.34 | €8.08 | x |
| 2018-12-31 | €0.67 | €8.08 | x |
| 2019-12-31 | €2.27 | €8.08 | x |
| 2020-12-31 | €-0.42 | €8.08 | x |
| 2021-12-31 | €2.14 | €8.08 | x |
| 2022-12-31 | €1.90 | €8.08 | x |
| 2023-12-31 | €1.37 | €8.08 | x |
| 2024-12-31 | €1.38 | €8.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genfit S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.25%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.19x
- Recent ROE (2.18%) is above the historical average (-50.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 29.12% | 23.85% | 0.41x | 2.95x | €1.69 Million |
| 2004 | 18.65% | 17.33% | 0.41x | 2.65x | €997.54K |
| 2005 | 13.29% | 13.88% | 0.41x | 2.31x | €438.76K |
| 2006 | 1.18% | 3.26% | 0.22x | 1.67x | €-2.45 Million |
| 2007 | -11.04% | -29.55% | 0.24x | 1.59x | €-5.34 Million |
| 2008 | -17.70% | -45.21% | 0.19x | 2.05x | €-6.20 Million |
| 2009 | -47.51% | -126.87% | 0.15x | 2.48x | €-8.93 Million |
| 2010 | -111.82% | -249.65% | 0.12x | 3.74x | €-10.22 Million |
| 2011 | -217.22% | -410.09% | 0.08x | 6.52x | €-10.13 Million |
| 2012 | -79.19% | -323.60% | 0.07x | 3.45x | €-6.09 Million |
| 2013 | -89.78% | -666.15% | 0.07x | 2.07x | €-14.06 Million |
| 2014 | -24.17% | -1054.60% | 0.02x | 1.23x | €-24.07 Million |
| 2015 | -30.92% | -3251.42% | 0.01x | 1.25x | €-22.68 Million |
| 2016 | -23.58% | -11854.58% | 0.00x | 1.16x | €-47.95 Million |
| 2017 | -56.23% | -49664.41% | 0.00x | 2.81x | €-69.03 Million |
| 2018 | -379.77% | -115247.83% | 0.00x | 10.96x | €-81.61 Million |
| 2019 | -77.49% | -211.24% | 0.10x | 3.69x | €-73.55 Million |
| 2020 | 0.00% | -13231.50% | 0.00x | 0.00x | €-99.60 Million |
| 2021 | 56.47% | 84.00% | 0.28x | 2.37x | €55.35 Million |
| 2022 | -25.09% | -117.45% | 0.09x | 2.28x | €-33.17 Million |
| 2023 | -42.52% | -101.15% | 0.16x | 2.56x | €-35.69 Million |
| 2024 | 2.18% | 2.25% | 0.44x | 2.19x | €-5.42 Million |
Industry Comparison
This section compares Genfit S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $54,195,048
- Average return on equity (ROE) among peers: -104.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genfit S.A. (GNFT) | €52.47 Million | 29.12% | 3.13x | $399.59 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $123.48 Million |
| Abivax SA (ABVX) | $11.78 Million | -260.03% | 3.39x | $6.97 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $111.73 Million |
| Aelis Farma SA (AELIS) | $1.20 Million | -263.37% | 5.00x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $6.83 Million | -373.49% | 2.98x | $1.03 Million |
| Cellectis (ALCLS) | $450.27 Million | -17.48% | 0.11x | $282.27 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $21.67 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $30.11 Million |
| Integragen (ALINT) | $2.19 Million | 0.70% | 3.39x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more